Propanc Biopharma, a company that is developing treatments to stop cancer recurrence, has entered into a strategic financing agreement of up to $100 million with Hexstone Capital — an investment firm. The agreement begins with an initial $1 million investment through the issuance of Series C Convertible Preferred Stock. Each preferred share is convertible into common stock at an initial price of $5.00 per share, representing a 280% premium over Propanc’s recent closing price. The terms include ownership limits and alternative conversion options outlined in the company’s SEC filings. Hexstone will also receive 9,900 warrants to purchase additional preferred shares, providing up to $99 million in potential future funding. The company may call up to 500 warrants per month, enabling flexible capital access under agreed conditions. Image: Freepik